Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy.
Beveridge RA, Miller JA, Kales AN, Binder RA, Robert NJ, Heisrath-Evans J, Koczyk-Scripka K, Pashko S, Norgard MJ, Barnes HM, Taylor WR, Thompson KA, Smith LF, Ueno WM, Dobrzynski RF, Warren RD, Katcher D, Byrne PJ, Dunning DM, Winokur SH, Lockey JL, Cambareri RJ, Butler TP, Meister RJ, Fiegert JM.
Beveridge RA, et al. Among authors: warren rd.
Support Care Cancer. 1997 Jul;5(4):289-98. doi: 10.1007/pl00009894.
Support Care Cancer. 1997.
PMID: 9257425
Clinical Trial.